Fintel reports that on November 26, 2025, Chardan Capital maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 49.92% Upside As of ...

The Vanguard Mega Cap Value Index Fund ETF Shares ( MGV ), launched on 12/17/2007 and managed by The Vanguard Group, Inc., ...

The Global X SuperDividend ETF (SDIV) prioritizes yield above all else, generating a current payout just below 10% that's ...

Discover the Center for Research in Security Prices (CRSP) at the Booth School of Business, including its historical data on ...

The company, established in the aftermath of 9/11, has skyrocketed since the launch of its Artificial Intelligence Platform (AIP) in 2023, which added an AI layer to its deep data analytics platform.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Late last year, Lucid Group Inc. (NASDAQ: LCID) began ...

Crispr Therapeutics AG remains a Strong Buy, driven by forthcoming revenue following Casgevy's FDA/EMA approvals and a robust, expanding pipeline targeting high-value indications. CRSP's commercial ...

Wall Street forecasters expect the stock market to grind higher in 2026 as earnings grow, the Fed cuts rates, and the US ...

Given these factors, my favorite index ETF to outperform in 2026 is the Vanguard Mega Cap Growth ETF as it's one of the most ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Realty Income remains a staple in dividend investors’ ...

Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...